Skip to main content

Enliven Therapeutics

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for precision oncology applications. The company utilizes a chemistry-driven platform to engineer targeted therapies designed to overcome resistance mechanisms in cancer patients. Its lead clinical development pipeline includes ELVN-001, a selective tyrosine kinase inhibitor for chronic myeloid leukemia, and ELVN-002, a HER2-selective inhibitor targeting solid tumors. Core operations encompass pre-clinical targeted drug discovery, medicinal chemistry, clinical trial management, and biomarker discovery. As a clinical-stage development firm, the company currently generates limited commercial revenue, funding operations through equity capital, collaborations, and partnership agreements. Enliven occupies an emerging position in precision oncology innovation. The company is headquartered in Boulder, Colorado, United States, and its common stock trades on the Nasdaq Global Market.

7 of the funds FundTelligence covers report a position in Enliven Therapeutics.

Sector
Health Care
Country
United States
Funds holding it
7
Exposure themes
Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics

Funds holding Enliven Therapeutics

Loading...